The latest market report published by Credence Research, Inc. “Wilson’s Disease Drugs Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global Wilson’s disease drugs market was valued at US$ 372.5 Mn in 2016, and is expected to reach US$ 592.8 Mn by 2025 expanding at a CAGR of 5.19 % from 2017 to 2025.
Browse the full report Wilson’s Disease Drugs Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at https://www.credenceresearch.com/report/wilsons-disease-drugs-market
Free Sample Request: https://www.credenceresearch.com/sample-request/58947
Pharmaceutical manufacturers are currently focusing in addressing the abnormal copper metabolism to prevent the excessive deposition of copper in liver and other body organs. WTX101 also known as bis-choline tetrathiomolybdenate developed by Wilson Therapeutics AB is showing promising results in the phase 3 clinical trial study for treatment of Wilson’s disease. It is the first novel copper protein binding agent with unique mechanism of action. WTX101 has high specificity for copper and forms copper protein complexes and provides alternative mechanism for the transport of copper protein transport. Excessive copper levels are reduced in the blood and liver cells and promotes biliary excretion of copper. Gene therapy is also a feasible option which will transport functional ATPB7 gene via gene vectors.
Chelators are the first line of treatment for disease management of Wilson’s disease. They prevent the excessive deposition of copper in liver cells by expediting urine excretion of copper. Zinc is used in patients non-reactive to chelators therapy. It has less adverse events and used in long term therapy of Wilson’s disease.
The hepatic conditions are first diagnosed in patients suffering with Wilson’s disease due to large accumulation of copper in the liver cells causing an increase in aspartate aminotransferase and alanine aminotransferase. Neuropsychiatric symptoms are manifested in the later stages of the disease with patient showing symptoms of seizures, ataxia and tremors.
North America currently enjoys the leading position in Wilson’s disease treatment drugs market on account of rising prevalence of Wilson’s disease in Caucasian population and supportive regulatory environment provided by the USFDA for drugs employed in treatment of Wilson’s disease. Recent technological advancement in laboratory diagnostics in Asia Pacific has resulted in accurate diagnosis of patients suffering with Wilson’s disease. Asia Pacific has tremendous opportunity for its established generic market to manufacture drugs which are otherwise imported from western countries.
The pharmaceutical companies proactive in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Valeant Pharmaceuticals International, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., VHB Life Sciences, Inc. and Wilson Therapeutics AB.
Key Market Movements:
- Accurate diagnosis of symptoms has brought enormous patients suffering with Wilson’s disease in drug treatment regimen
- Orphan disease status has acquired supportive regulatory milieu for the novel drug discovery and development of Wilson’s disease
- Enormous opportunity for major pharma players to conduct clinical trials and establish R&D centers in developing nations with unmet medical needs
Based on Indication, the global Wilson’s disease drugs market is categorized into
- Others (Heart and Kidney Complications)
Wilson’s disease is a rare hereditary disorder which occurs due to the accumulation of copper in different body organs such as liver, brain, eyes and other vital organs. The disease takes place due to the mutation in ATP7B gene. The prevalence rate of Wilson’s disease is 1 in 30,000 persons, usually diagnosed in young and adult age group. Hepatic indications are first diagnosed in the disease manifestation of Wilson’s disease on account of reduced biliary excretion of copper results in excessive accumulation of copper in liver. The early symptoms manifested in liver indications are tiredness, hepatitis with elevated levels of gamma-glutamyl transpeptidase, alanine aminotransferase and aspartate aminotransferase. The neuropsychiatric symptoms are manifested in the later stages of the disease manifestation with the basal ganglia hampering the coordinate movement. The major symptoms are Parkinsonism, tremors, ataxia, dystonia and seizures. In approximately 90 % of the patients exhibiting neuropsychiatric symptoms shows the development of Kayser-Fleishcer rings (deposition of copper) in the cornea region of the eyes. The manufacturers that are active in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc. and Wilson Therapeutics AB.
Based on drug class, the Wilson’s disease drugs market is categorized into:
- Zinc Acetate
The primary diagnosis of Wilson’s disease is complicated as the symptoms are similar to other diseases such as hepatitis C, seizures, jaundice, heavy metal poisoning and cerebral palsy. Even though Wilson’s disease is a genetic hereditary disease but a person is not likely to acquire the ATPB7 mutation on receiving only one abnormal gene from either of the parents. The disease management is entirely focused on compensating for the abnormal copper metabolism. As if now the chelators are the first line of treatment for achieving symptomatic relief in patients suffering with Wilson’s disease. Chelators deplete the excessive copper levels in the body by expediting their excretion through urine, but being nonspecific to copper they bind and excrete other micronutrients form the body. The adverse effects related to chelators are severe such as bone marrow suppression and kidney complications thereby hampering its market growth. Zinc acetate is the only mineral recommended as an alternative therapy to chelators. It works by reducing the dietary uptake of copper in the gastrointestinal tract and excretes it through feces. Its effect are extremely slow therefore used for maintenance therapy only.
For the purpose of this study, the global Wilson’s disease drugs market is categorized into the following regional and country specific markets:
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- Rest of Middle East and Africa
According to the U.S. Department of Health and Human Services in 2015 countrywide survey the prevalence of Wilson’s disease in the United States is 1 in 55,000 births with the Wilson’s disease allele frequency rate of 0.00428. North America is the most significant market in the Wilson’s disease treatment drugs market on account of high Wilson’s disease heterozygote frequency rate of 0.855% in the Caucasian population. The autosomal recessive rate of Wilson’s disease is approximately 25% in Europe with patients being resistant to chelators therapy and E.U. approving only zinc acetate for Wilson’s disease management in Europe. Being an orphan disease the European Medical Agency is proactively investing in the novel drug discovery for Wilson’s disease. The neuropsychiatric indications related to Wilson’s disease are on a rise in Asia Pacific. The market is heavily dependent on treatment drugs imported from U.S. and Europe which creates a huge opportunity for the existing generic market in Asia Pacific…
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Company Name: Credence Research, Inc.
Contact Person: Chris Smith, Global Sales Manager
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
Country: United States